PE20050191A1 - Composicion farmaceutica que comprende dipiridamol, acido acetilsalicilico y un antagonista de angiotensina ii - Google Patents

Composicion farmaceutica que comprende dipiridamol, acido acetilsalicilico y un antagonista de angiotensina ii

Info

Publication number
PE20050191A1
PE20050191A1 PE2004000151A PE2004000151A PE20050191A1 PE 20050191 A1 PE20050191 A1 PE 20050191A1 PE 2004000151 A PE2004000151 A PE 2004000151A PE 2004000151 A PE2004000151 A PE 2004000151A PE 20050191 A1 PE20050191 A1 PE 20050191A1
Authority
PE
Peru
Prior art keywords
dipyridamol
angiotensin
antagonist
pharmaceutical composition
composition including
Prior art date
Application number
PE2004000151A
Other languages
English (en)
Spanish (es)
Inventor
James C Gilbert
Lutz Hilbrich
Axel Riedel
David Michael Humphreys
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32870338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050191(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20050191A1 publication Critical patent/PE20050191A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2004000151A 2003-02-13 2004-02-11 Composicion farmaceutica que comprende dipiridamol, acido acetilsalicilico y un antagonista de angiotensina ii PE20050191A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10306179A DE10306179A1 (de) 2003-02-13 2003-02-13 Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe
EP03018212 2003-08-08

Publications (1)

Publication Number Publication Date
PE20050191A1 true PE20050191A1 (es) 2005-04-12

Family

ID=32870338

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000151A PE20050191A1 (es) 2003-02-13 2004-02-11 Composicion farmaceutica que comprende dipiridamol, acido acetilsalicilico y un antagonista de angiotensina ii

Country Status (29)

Country Link
US (5) US20040214802A1 (enExample)
EP (2) EP1733729A1 (enExample)
JP (1) JP2006517557A (enExample)
KR (1) KR20050100676A (enExample)
CN (1) CN1750830A (enExample)
AR (1) AR043173A1 (enExample)
AT (1) ATE395921T1 (enExample)
AU (1) AU2004212305A1 (enExample)
BR (1) BRPI0407457A (enExample)
CA (1) CA2515941A1 (enExample)
DE (2) DE10306179A1 (enExample)
DK (1) DK1603573T3 (enExample)
EA (1) EA200501231A1 (enExample)
EC (1) ECSP055963A (enExample)
ES (1) ES2308147T3 (enExample)
HR (1) HRP20050713A2 (enExample)
MX (1) MXPA05008572A (enExample)
NO (1) NO20054216L (enExample)
NZ (1) NZ542302A (enExample)
PE (1) PE20050191A1 (enExample)
PL (1) PL378204A1 (enExample)
PT (1) PT1603573E (enExample)
RS (1) RS20050618A (enExample)
SI (1) SI1603573T1 (enExample)
TW (1) TW200501957A (enExample)
UA (1) UA83481C2 (enExample)
UY (1) UY28182A1 (enExample)
WO (1) WO2004071385A2 (enExample)
ZA (1) ZA200505956B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
DE10306179A1 (de) * 2003-02-13 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe
CA2437709A1 (en) * 2003-08-08 2005-02-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of dipyridamole, acetylsalicylic acid and an angiotensin ii antagonist for treatment and prevention of vascular events
JP2005060359A (ja) * 2003-08-13 2005-03-10 Boehringer Ingelheim Pharma Gmbh & Co Kg 血管系病態の治療及び予防のためのジピリダモール、アセチルサリチル酸及びアンギオテンシンｉｉ拮抗薬の使用
WO2009080301A1 (en) * 2007-12-21 2009-07-02 Boehringer Ingelheim International Gmbh Treatment and prevention of ischaemic cerebral lesions and cerebrovascular cognitive impairment using a treatment regimen consisting of dipyridamole and an angiotensin ii receptor blocker in patients with previous stroke
WO2009100534A1 (en) * 2008-02-14 2009-08-20 Kardiatech, Inc. Combination therapy to treat vascular disorders
US20100069326A1 (en) * 2008-02-14 2010-03-18 Wasimul Haque Combination Therapies to Treat Cardio- and Cerebro-Vascular Disorders
WO2010097501A2 (en) * 2009-02-26 2010-09-02 Orion Corporation A combination treatment
US8633158B1 (en) * 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
WO2016119701A1 (en) 2015-01-28 2016-08-04 Realinn Life Science Limited COMPOUNDS FOR ENHANCING PPARγ EXPRESSION AND NUCLEAR TRANSLOCATION AND THERAPEUTIC USE THEREOF

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3031458A (en) * 1958-02-05 1962-04-24 Ciba Pharm Prod Inc Isoindolines
US3031450A (en) 1959-04-30 1962-04-24 Thomae Gmbh Dr K Substituted pyrimido-[5, 4-d]-pyrimidines
US3317279A (en) * 1963-03-15 1967-05-02 Pennsalt Chemicals Corp Polymorph of calcium disilicide and its method of preparation
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
DE3000979A1 (de) 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
US4318477A (en) * 1980-09-22 1982-03-09 Kerpe Stase Z Pharmaceutical package
DE3124090A1 (de) 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
DE3627423A1 (de) 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
SI9210098B (sl) 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
EP1013273A1 (en) 1998-12-23 2000-06-28 Novartis AG Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
JP2002138054A (ja) * 2000-08-25 2002-05-14 Takeda Chem Ind Ltd フィブリノーゲン低下剤
JP2002293742A (ja) * 2001-01-29 2002-10-09 Takeda Chem Ind Ltd 鎮痛・抗炎症剤
JP2003212758A (ja) * 2001-03-16 2003-07-30 Takeda Chem Ind Ltd 徐放性製剤の製造法
DE10306179A1 (de) * 2003-02-13 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe

Also Published As

Publication number Publication date
ATE395921T1 (de) 2008-06-15
SI1603573T1 (sl) 2008-10-31
HRP20050713A2 (en) 2006-09-30
ECSP055963A (es) 2006-01-16
KR20050100676A (ko) 2005-10-19
EP1603573B8 (en) 2009-04-01
US20070004687A1 (en) 2007-01-04
WO2004071385A2 (en) 2004-08-26
EP1603573A2 (en) 2005-12-14
RS20050618A (sr) 2007-09-21
EP1733729A1 (en) 2006-12-20
US20040214802A1 (en) 2004-10-28
CA2515941A1 (en) 2004-08-26
BRPI0407457A (pt) 2006-01-31
DE10306179A1 (de) 2004-08-26
ZA200505956B (en) 2006-03-29
ES2308147T3 (es) 2008-12-01
UY28182A1 (es) 2004-09-30
US20080188497A1 (en) 2008-08-07
TW200501957A (en) 2005-01-16
DK1603573T3 (da) 2008-09-15
EA200501231A1 (ru) 2006-02-24
NO20054216D0 (no) 2005-09-12
UA83481C2 (uk) 2008-07-25
AU2004212305A1 (en) 2004-08-26
WO2004071385A3 (en) 2005-01-06
DE602004013937D1 (de) 2008-07-03
CN1750830A (zh) 2006-03-22
US20060241089A1 (en) 2006-10-26
PT1603573E (pt) 2008-06-26
NO20054216L (no) 2005-09-12
JP2006517557A (ja) 2006-07-27
US20080113949A1 (en) 2008-05-15
AR043173A1 (es) 2005-07-20
MXPA05008572A (es) 2005-11-04
NZ542302A (en) 2008-12-24
EP1603573B1 (en) 2008-05-21
PL378204A1 (pl) 2006-03-20

Similar Documents

Publication Publication Date Title
CR11854A (es) Compuestos de piridina
GT201200147A (es) Antagonistas de espiro-oxindol de mdm2
GT201700056A (es) Uso de agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamento de la enfermedad del hígado graso no alcohólico.
HN2011001593A (es) Piridiloxi-indoles del vegf-r2 y uso de los mismos para el tratmiento de enfermedades
ECSP077324A (es) Amidas bicíclicas como inhibidores de cinasa
ECSP066990A (es) Formulaciones con liberación controlada de principio activo que contienen vardenafilo
PA8849701A1 (es) Forma de dosificacion farmaceutica que comprende nifedipino o nisoldipino y un antagonista de anglotensina ii y/o un diuretico
NI201300041A (es) Antagonistas de mdm2 de espiro-oxindol
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
GT200900328A (es) Derivados de bencimidazol
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
AR116999A1 (es) Conjugados citostáticos con ligandos de integrina
GT201300235A (es) Uso de 2,3-dihidroimidazo (1,2-c) quinazolinas sustituidas
CL2008001297A1 (es) N-[(1s)-1-(5-fluoropirim idin-2-i1 )etil]-3-(5-isopropoxi-1 h-pirazol-3-il )-3h-imidazo[4,5-b]piridin-5amina o una sal farmacéuticamente aceptabie del mismo; composición farmacéutica que lo comprende; y su uso en el tratamiento del cáncer.
GT200600445A (es) Formas de presentación farmaceuticas solidas de administración oral con liberacion rapida del principio activo.
CL2008001946A1 (es) Compuestos derivados de imidazol, antagonistas de receptores ccr2, ccr3, ccr5; procedimiento de preparacion; y uso en el tratamiento de enfermedades vasculares perifericas.
CL2008002984A1 (es) Composicion farmaceutica que comprende micofenolato sodico y su uso para el tratamiento y/o prevencion en enfermedades autoinmunes tales como el rechazo de aloinjertos o xenoinjertos de organos, celulas o tejidos y como antiinflamatorio.
AR047928A1 (es) Derivados de tetrahidropiridoindol
UY29561A1 (es) Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
AR053651A1 (es) Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama
GT200600517A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
PA8803201A1 (es) Derivados acidos de cicloalquilamino
PA8586201A1 (es) Nuevas formulaciones de liberacion prolongada inyectables
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
MX2013000694A (es) Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed